Boston Scientific (NYSE: BSX) has received a range of analyst ratings, reflecting a mix of bullish and bearish sentiments. Over the past month, there have been 7 bullish, 9 somewhat bullish, and 1 indifferent rating, with no bearish ratings in sight. The average 12-month price target stands at $69.24, with a range from $62.00 to $80.00, signaling a 10.78% increase from the previous average target of $62.50.
Recent analyst actions have been notably positive:
Joshua Jennings of TD Cowen upgraded the rating to Outperform, setting a price target of $77.00.
Joanne Wuensch from Citigroup raised the rating to Buy, with a price target of $71.00.
Mike Matson of Needham also upgraded to Buy, with a price target of $71.00.
Jayson Bedford from Raymond James raised the rating to Strong Buy, setting a price target of $73.00.
Steven Lichtman of Oppenheimer upgraded to Perform, with a price target of $68.00.
Overall, analysts are optimistic about Boston Scientific’s future performance, as recent ratings trend towards positive outlooks and higher price targets.
Boston Scientific Corporation (BSX) Stock Sees Positive Performance on March 7, 2024
On March 7, 2024, Boston Scientific Corporation (BSX) saw a positive performance in the stock market. According to data from CNN Money, BSX was trading near the top of its 52-week range and above its 200-day simple moving average. The price of BSX shares increased by $0.40 since the market last closed, representing a 0.59% rise. The stock closed at $67.82, showing a strong performance throughout the trading day. Additionally, in after-hours trading, BSX continued to see gains, with the stock rising by $0.23. This positive momentum in BSX stock can be attributed to various factors, including strong financial performance, positive news or developments within the company, or overall market conditions. Investors may have been encouraged by the stock’s upward movement and potential for further growth. It is important for investors to continue monitoring BSX’s performance and staying informed about any news or developments that may impact the stock price. While past performance is not indicative of future results, the positive momentum seen on March 7, 2024, may be a promising sign for BSX investors.
Boston Scientific Corporation Reports Strong Financial Performance in 2024: Total Revenue Reaches $14.24 Billion
On March 7, 2024, Boston Scientific Corporation (BSX) reported strong financial performance with total revenue reaching $14.24 billion for the past year and $3.73 billion for the fourth quarter. This represents a 12.29% increase in total revenue compared to the previous year and a 5.61% increase compared to the previous quarter. The company also reported a net income of $1.59 billion for the past year and $504.00 million for the fourth quarter. This marks a significant 128.22% increase in net income compared to the previous year, although it held flat compared to the previous quarter. Earnings per share (EPS) for Boston Scientific Corporation were reported at $1.07 for the past year and $0.34 for the fourth quarter. This represents a substantial 140.59% increase in EPS compared to the previous year, although it remained flat compared to the previous quarter. Overall, Boston Scientific Corporation has shown strong financial performance over the past year, with significant increases in total revenue and net income. The company’s earnings per share also saw impressive growth compared to the previous year. Investors and analysts may view these results positively, indicating that BSX stock may be performing well and potentially offering good returns for shareholders. It will be interesting to see how the market responds to these strong financial results and whether BSX stock prices will reflect the company’s solid performance.
